Imagin Medical, Inc. engages in the research, development, and commercialization in the device and instrumentation medical technology industry. The company is headquartered in Vancouver, British Columbia. The firm is engaged in developing technologies to better visualize and treat urologic cancers through minimally invasive surgery, including bladder and prostate cancer. Its first product, enCAGE Coil, is designed to eliminate the limitations of other methods of prostate cancer treatment that can cause erectile dysfunction and urinary incontinence. The device is a disposable, focal therapy, precision ablation system that delivers bipolar, radio frequency energy through a distinctive coil electrode, or cage. The company enables the surgeon to preset margins for precise tissue targeting. Its second product, the i/Blue Imaging System, will bring several key technological advancements that improve the utility of blue light imaging for visualizing bladder cancer. The i/Blue System delivers blue light imaging technology in a more versatile, practical, and accessible format and is designed to work with existing fiberoptic endoscopes on the market.
최신 재무제표(Form-10K)에 따르면, Imagin Medical Inc.의 총 자산은 $1이며, 순손실입니다.
IMEXF의 주요 재무 비율은 무엇인가요?
Imagin Medical Inc.의 유동비율은 0.07이고, 순이익률은 0, 주당 매출은 $0입니다.
Imagin Medical Inc.의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
Imagin Medical Inc. 주요 수익원은 Transformative Cell and Exosome-based Therapeutics이며, 최신 수익 발표에서 수익은 22,270,465입니다. 지역별로는 United States이 Imagin Medical Inc.의 주요 시장이며, 수익은 22,270,465입니다.
Imagin Medical Inc.은 수익성이 있나요?
no, 최신 재무제표에 따르면 Imagin Medical Inc.의 순손실은 $-2입니다.